Why Nkarta, Inc.’s (NKTX) Stock Is Down 5.44%
As of Friday, October 16, Nkarta, Inc.’s NKTX share price has dipped by 5.44%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Commentary & Analysis
Why Nkarta, Inc.’s (NKTX) Stock Is Down 5.07%
As of Tuesday, October 13, Nkarta, Inc.’s NKTX share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Nkarta, Inc.’s (NKTX) Stock Is Down 5.77%
As of Tuesday, October 06, Nkarta, Inc.’s NKTX share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nkarta, Inc.’s (NKTX) Stock Is Down 6.44%
As of Wednesday, September 23, Nkarta, Inc.’s NKTX share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Nkarta, Inc.’s (NKTX) Stock Is Up 5.90%
As of Wednesday, September 16, Nkarta, Inc.’s NKTX share price has surged by 5.90%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $125.3 | $228.7 | 24% |
|
| Shares Out (Mil) | 74.5 | 53.9 | 56% |
|
| Institutional Ownership | 99.5% | 92.9% | 89% |
|
| Float (Mil) | 60.6 | 42.1 | 51% |
|
| Beta | 0.98 | 0.95 | 58% |
|
| Avg Daily Volume (000s) | 1,062 | 574 | 71% |
|
| Price Change (52-week) |
(28.3%) | 47.3% | 31% |
|
| Growth | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (2.6%) | (10.1%) | 36% |
|
| EPS (5yr) | 23.7% | 15.8% | 74 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.8%) | (15.7%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.383) | ($1.707) | ($1.753) | |
| Month Ago EPS | ($0.383) | ($1.707) | ($1.753) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.370) | ($1.480) | ($1.650) | |
| Year/Year Chg | (29.3%) | 21.3% | 14.1% | |
| Financials | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($117) | ($44) | 10% |
|
| EPS (TTM) | ($1.581) | ($1.500) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($93) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($29) | $2 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $66 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $97 | $177 | 21% |
|
| Valuation | NKTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.51 | 2.24 | 10% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (29.9%) | (47.0%) | 17% |
|
| ROE | (38.8%) | (54.1%) | 18% |
|
| Liabilities to Assets | 26.6% | 29.1% | 18% |
|
| F-Score | 1 | 2 | 1% |
|
Nkarta, Inc. did not pass any screens on 10/21/2026.
